A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
They tend to be reactive towards metals, except for the noble gases, which are inert towards most substances. They are brittle when solid as their atoms are held tightly in place. They are less dense and conduct electricity poorly, because there are no mobile electrons. Near the borderline, band gaps are small and thus many elements in that region are semiconductors, such as silicon, germanium, and tellurium. Selenium has both a semiconducting grey allotrope and an insulating red allotrope; arsenic has a metallic grey allotrope, a semiconducting black allotrope, and an insulating yellow allotrope (though the last is unstable at ambient conditions). Again there are exceptions; for example, diamond has the highest thermal conductivity of all known materials, greater than any metal. It is common to designate a class of metalloids straddling the boundary between metals and nonmetals, as elements in that region are intermediate in both physical and chemical properties. However, no consensus exists in the literature for precisely which elements should be so designated. When such a category is used, silicon, germanium, arsenic, and tellurium are almost always included, and boron and antimony usually are; but most sources include other elements as well, without agreement on which extra elements should be added, and some others subtract from this list instead. For example, unlike all the other elements generally considered metalloids or nonmetals, antimony's only stable form has metallic conductivity.
According to Richards, Campania, & Muse-Burke, "There is growing evidence that is showing emotional abilities are associated with pro-social behaviors such as stress management and physical health." Their research also concluded that people who lack emotional expression are inclined to anti-social behaviors (e.g., substance use disorder and alcohol use disorder, physical fights, vandalism), which reflects one's mental health and suppressed emotions. Adults and children who face mental illness may experience social stigma, which can exacerbate the issues.
In biology, hemostasis or haemostasis is a process to prevent and stop bleeding, meaning to keep blood within a damaged blood vessel (the opposite of hemostasis is hemorrhage). It is the first stage of wound healing. Hemostasis involves three major steps:
Because so many chloroplast genes have been moved to the nucleus, many proteins that would originally have been translated in the chloroplast are now synthesized in the cytoplasm of the plant cell. These proteins must be directed back to the chloroplast, and imported through at least two chloroplast membranes. Curiously, around half of the protein products of transferred genes aren't even targeted back to the chloroplast. Many became exaptations, taking on new functions like participating in cell division, protein routing, and even disease resistance. A few chloroplast genes found new homes in the mitochondrial genome—most became nonfunctional pseudogenes, though a few tRNA genes still work in the mitochondrion. Some transferred chloroplast DNA protein products get directed to the secretory pathway, though many secondary plastids are bounded by an outermost membrane derived from the host's cell membrane, and therefore topologically outside of the cell because to reach the chloroplast from the cytosol, the cell membrane must be crossed, which signifies entrance into the extracellular space. In those cases, chloroplast-targeted proteins do initially travel along the secretory pathway. Because the cell acquiring a chloroplast already had mitochondria (and peroxisomes, and a cell membrane for secretion), the new chloroplast host had to develop a unique protein targeting system to avoid having chloroplast proteins being sent to the wrong organelle.
Sources: en.wikipedia.org
Eryngium planum, the blue eryngo or flat sea holly, is a species of flowering plant in the family Apiaceae, native to the area that includes central and southeastern Europe and Central Asia. It is a thistle-like herbaceous perennial growing to 50 cm (20 in) with branched silvery-blue stems, and numerous small blue conical flowerheads surrounded by spiky bracts in summer.
A degron can be converted into its active form by a post-translational modification such as phosphorylation of a tyrosine, serine or threonine residue. In this case, the ubiquitin ligase exclusively recognizes the phosphorylated version of the substrate due to stabilization within the binding site. For example, FBW7, the F-box substrate recognition unit of an SCFFBW7ubiquitin ligase, stabilizes a phosphorylated substrate by hydrogen binding its arginine residues to the phosphate, as shown in the figure to the right. In absence of the phosphate, residues of FBW7 repel the substrate.
{\displaystyle \left(\mathbf {w} _{i},{\frac {\partial \mathbf {u} _{j}}{\partial t}}\right)=-{\bigl (}\mathbf {w} _{i},\left(\mathbf {u} \cdot \nabla \right)\mathbf {u} _{j}{\bigr )}-\nu \left(\nabla \mathbf {w} _{i}:\nabla \mathbf {u} _{j}\right)+\left(\mathbf {w} _{i},\mathbf {f} ^{S}\right).}
Sources: en.wikipedia.org
=== White Sands trackway and peopling of North America === The earliest compelling evidence for human habitation of the Americas comes from the Clovis complex, between 11,050 and 10,800 14C yr B.P. However, a series of human tracks were identified at White Sands National Park, New Mexico, which have been dated contentiously dated to between 23,000 and 21,000 years ago - during the Last Glacial Maximum. Alongside anatomically modern humans, the trackway shows impressions created by a Columbian mammoth and a giant ground sloth. The upper biostratigraphic limit for when the impressions were made could therefore be determined by consideration of the extinction dates of mammoths and ground sloths. More precise dates were able to be gained via radiocarbon dating of ditch grass (ruppia cirrhosa) embedded in the prints. These seeds produced a date of 23,000-21,000 years ago. However, 14C dates are not infallible, and this remains a topic of debate. A recent counterproposal posits that the trackways were, in fact, created by the Clovis culture and the pre-existing proposed dates of first habitation should not be moved. False dates may have been produced as older strata containing the seeds could have been eroded and displaced onto the damp clay, before being impressed in by footsteps. Alternatively, aquatic plants like ditch grass reflect the 14C levels in their environment when living, if 14C was deficient in the habitat, this could imply a false date.
=== Constituents === Nutmeg consists of 25 to 40% fatty oils or triglycerides (nutmeg butter), 7 to 16% volatile oils, and 45 to 60% pulp or structural components like cellulose. The triglyceride part is mostly trimyristin, but triolein and trilinolein are also found in small amounts. The psychoactive component of nutmeg appears to be the volatile oil component, with most of the rest inactive in animals and humans. It consists 80% of a terpene fraction, 10 to 15% of an aromatic fraction, and the small remainder fatty acids. Turpentine, a fluid made from the resin mainly of pine trees, has a similar composition as the terpene fraction of nutmeg, but has no reputation for producing intoxicating effects. The aromatic fraction of nutmeg consists of a number of allylbenzenes (propenylbenzenes), mainly myristicin, elemicin, and safrole (these three 84–95%), but also including methyleugenol, methylisoeugenol, methoxyeugenol, isoeugenol, eugenol, and isoelemicin. A 20 gram amount of nutmeg contains about 210 mg myristicin, 70 elemicin, 39 mg safrole, as well as 3 to 18 mg each of the other compounds. Myristicin makes up approximately 1.3% of whole nutmeg and about 4 to 13% of the volatile oil fraction. Myristicin and elemicin have been thought to be nutmeg's psychoactive constituents, whereas safrole and the various eugenols seem to be inactive with regard to such effects. Though other nutmeg components are inactive, they might aid in the absorption of the active constituents.
The CDC defines an adult (a person aged 20 years or greater) with a body mass index (BMI) of 30 or greater as obese and an adult with a BMI of 25.0 to 29.9 as overweight. Obesity in adults is divided into three categories. Adults with a BMI of 30 to 34.9 have class 1 obesity; adults with a BMI of 35 to 39.9 have class 2 obesity; adults with a BMI of 40 or greater have class 3 obesity, which is also known as extreme or severe obesity (and was formerly known as morbid obesity). Children (persons aged 2 to 19 years) with a BMI at or above the 95th percentile of children of the same age and sex are defined as obese, and children with a BMI at or above the 85th percentile but less than the 95th percentile are defined as overweight. Compared to non-obese Americans, between 2001 and 2016, obese Americans incurred an average of $2,505 more in medical expenses annually, and in 2016, the aggregate medical cost due to obesity in the United States of America was $260.6 billion. However, some evidence suggests the lifetime cost of medical treatment for obese individuals is lower than for healthy weight individuals. This is because healthy weight people live longer statistically and tend to develop chronic diseases that need to be continually treated into old age, whereas obese people tend to die from metabolic diseases at younger ages and avoid some of those protracted medical costs.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.